Skip to main content
OpenTrials
Completed

NCT Number: NCT02794922

Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain

The purpose of this study is to determine effectiveness of vitamin B in reducing temporomandibular joint disorder (TMD) pain. Patients will be randomised to receive the study drug or placebo. The study drug we are using is a combination of vitamin B1(thiamine mononitrate)-242.5mg; vitamin B6(pyridoxineHCl)-250mg, and vitamin B12(cyanocobalamin)-1mg. We will assess patient's pain level, range of jaw movement and record any side effects from using this medication.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Prince Philip Dental Hospital

Hong Kong, China

About this study

Type of study : Prospective double blinded randomized control trial Sample population : patients with temporomandibular joint disorder pain who are currently undergoing treatment in Oral & Maxillofacial surgery unit, Prince Philip Dental Hospital Study Period : 2 year (1st may2015 to 1st may 2017)

Data Collection All new cases or existing TMD patients treated in oral maxillofacial surgery department, Prince Philip Dental Hospital will be acquired and screened based on inclusion and exclusion criteria. Selected patients will be categorised based on TMD axis 1 diagnosis and divided into two groups - group 1(Vitamin B) and group 2(placebo) randomly . Allocation of patients into the group will be based on computer generated by random block sequence.

Complete social demographic background of the patient will recorded according to the following format age, gender, race, education, and job.

Clinical assessment will be done to check 1. Mouth opening 2. Lateral excursion (right and left) 3. Protrusion 4. Deviation of lower jaw on opening 5. Tenderness of muscle of mastication 6. Pain - based on 10cm visual analog score.

After initial assessments, patients will be started on either vitamin B complex or placebo based on their group.

  • Both group of patients will be also prescribed with Tab Ibuprofen 400mg to be taken during acute Temporomandibular joint (TMJ) pain symptoms.
  • These patients will be reviewed on week 0,2,4 and 6.
  • All the patients will be reviewed by blinded assessor. Each patient will be given a log book to document frequency of TMJ pain attack, maximum pain score on each attack and amount of analgesics (Ibuprofen 400mg tabs) taken.
  • Log book record will be checked on their review.
  • Amount of analgesics recorded in log book and compliance of Vitamin B or placebo will be cross checked with remaining tablet count.

Data Evaluation/ Statistical Analyses The statistical analysis of this study will use the standard version of Statistical Package for the Social Sciences (SPSS) version 17.0 for windows. All the data will be gathered and entered in into this software.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • minimum age of 18
  • temporomandibular joint disorder with pain
  • chronic condition- symptoms lasting more than 3 months with at least 2 episodes of pain in last 1 month
  • language competence- in Cantonese or English
  • all ethnicity

Exclusion criteria

  • ankylosis of the joint
  • limited mental capacity
  • pregnancy and lactating mothers
  • inability to take medications (NSAIDS-Ibuprofen or Vitamin B)
  • undergoing concurrent pharmacotherapy with anti inflammatory or muscle relaxant medications
  • poor general health
  • history of TMJ trauma or TMJ surgery
  • subjects taking Vitamin B for other uses

Treatment and study plan

Neurovit Forte

Drug

Other names: Vitamin B Complex

Corn Starch

Drug

Primary outcomes

  1. Visual Analog Scale(VAS) Pain Score

    Time frame: baseline

    assessment of pain level with VAS score at baseline (week 0)

  2. Visual Analog Scale(VAS) Pain Score

    Time frame: week 2

    assessment of pain level with VAS score at week2

  3. Visual Analog Scale(VAS) Pain Score

    Time frame: week 4

    assessment of pain level with VAS score at week4

  4. Visual Analog Scale(VAS) Pain Score

    Time frame: week 6

    assessment of pain level with VAS score at week6

Secondary outcomes

  1. mouth opening measurement in millimeter (mm)

    Time frame: baseline

    assessment of mouth opening in millimeter (mm) at baseline (week0)

  2. mouth opening measurement in millimeter (mm)

    Time frame: week 2

    assessment of mouth opening in millimeter (mm) at week 2

  3. mouth opening measurement in millimeter (mm)

    Time frame: week4

    assessment of mouth opening in millimeter (mm) at week 4

  4. mouth opening measurement in millimeter (mm)

    Time frame: week 6

    assessment of mouth opening in millimeter (mm) at week 6

  5. number of participants with treatment related adverse events as assessed by CTCAE v4.03

    Time frame: 6 weeks

    Subjects will be assessed for any adverse events related to intervention , by using CYCAE v4.03, at week 0, week 2, week 4 and week 6

  6. tablet count measurements to check complaince

    Time frame: 6 weeks

    remaining tablets will be counted at end of Week 6 to check compliance rate towards treatment

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Jun 9, 2016
Registry last updated
May 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.